Mendus Q3 2023: ADVANCE II survival update at ASH - Redeye

Redeye provides its comment on Mendus’ Q3 2023 report. We judge that the most critical catalysts for the share will be interim readouts and top-line data from the company’s planned phase II trial in AML maintenance, combining vididencel and oral azacytidine. In the short term, an ADVANCE II survival update at ASH in December might act as a catalyst. We do some housekeeping in our model.

Länk till analysen i sin helhet: https://www.redeye.se/research/957476/mendus-q3-2023-advance-ii-survival-update-at-ash?utm_source=finwire&utm_medium=RSS